IPVS policy statement on HPV nucleic acid testing guidance for those utilising/considering HPV as primary precancer screening : Quality assurance and quality control issues
Copyright © 2022. Published by Elsevier B.V..
We advise that only clinically validated HPV assays which have fulfilled internationally accepted performance criteria be used for primary cervical screening. Further, assays should be demonstrated to be fit for purpose in the laboratory in which they will ultimately be performed, and quality materials manuals and frameworks will be helpful in this endeavor. Importantly, there is a fundamental shortage of well validated, low-cost, low complexity HPV tests that have demonstrated utility in a near-patient setting; representing a significant challenge and focus for future development in order to reach the WHO's goal of eliminating cervical cancer.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:159 |
|---|---|
| Enthalten in: |
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology - 159(2023) vom: 01. Feb., Seite 105349 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Garland, Suzanne M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cervical |
|---|
| Anmerkungen: |
Date Completed 24.01.2023 Date Revised 01.02.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jcv.2022.105349 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350959536 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350959536 | ||
| 003 | DE-627 | ||
| 005 | 20231226050158.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jcv.2022.105349 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1169.xml |
| 035 | |a (DE-627)NLM350959536 | ||
| 035 | |a (NLM)36584621 | ||
| 035 | |a (PII)S1386-6532(22)00281-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Garland, Suzanne M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a IPVS policy statement on HPV nucleic acid testing guidance for those utilising/considering HPV as primary precancer screening |b Quality assurance and quality control issues |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.01.2023 | ||
| 500 | |a Date Revised 01.02.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022. Published by Elsevier B.V. | ||
| 520 | |a We advise that only clinically validated HPV assays which have fulfilled internationally accepted performance criteria be used for primary cervical screening. Further, assays should be demonstrated to be fit for purpose in the laboratory in which they will ultimately be performed, and quality materials manuals and frameworks will be helpful in this endeavor. Importantly, there is a fundamental shortage of well validated, low-cost, low complexity HPV tests that have demonstrated utility in a near-patient setting; representing a significant challenge and focus for future development in order to reach the WHO's goal of eliminating cervical cancer | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cervical | |
| 650 | 4 | |a HPV | |
| 650 | 4 | |a Primary | |
| 650 | 4 | |a Screening | |
| 650 | 4 | |a Validation | |
| 650 | 7 | |a Nucleic Acids |2 NLM | |
| 700 | 1 | |a Iftner, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Cuschieri, Kate |e verfasserin |4 aut | |
| 700 | 1 | |a Kaufmann, Andreas M |e verfasserin |4 aut | |
| 700 | 1 | |a Arbyn, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a de Sanjose, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Poljak, Mario |e verfasserin |4 aut | |
| 700 | 1 | |a Dillner, Joakim |e verfasserin |4 aut | |
| 700 | 1 | |a Unger, Elizabeth R |e verfasserin |4 aut | |
| 700 | 0 | |a IPVS Policy Committee |e verfasserin |4 aut | |
| 700 | 1 | |a Garland, Suzanne M |e investigator |4 oth | |
| 700 | 1 | |a Stanley, Margaret |e investigator |4 oth | |
| 700 | 1 | |a Moscicki, Anna-Barbara |e investigator |4 oth | |
| 700 | 1 | |a Woo, Yin Ling |e investigator |4 oth | |
| 700 | 1 | |a Bhatla, Neerja |e investigator |4 oth | |
| 700 | 1 | |a Chan, Karen L |e investigator |4 oth | |
| 700 | 1 | |a Palefsky, Joel |e investigator |4 oth | |
| 700 | 1 | |a Giuliano, Anna R |e investigator |4 oth | |
| 700 | 1 | |a Kaufmann, Andreas M |e investigator |4 oth | |
| 700 | 1 | |a de Sanjose, Silvia |e investigator |4 oth | |
| 700 | 1 | |a Brotherton, Julia M L |e investigator |4 oth | |
| 700 | 1 | |a Feldman, Sarah |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology |d 1997 |g 159(2023) vom: 01. Feb., Seite 105349 |w (DE-627)NLM097223964 |x 1873-5967 |7 nnns |
| 773 | 1 | 8 | |g volume:159 |g year:2023 |g day:01 |g month:02 |g pages:105349 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jcv.2022.105349 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 159 |j 2023 |b 01 |c 02 |h 105349 | ||